Facial Prediction Technology for Edentulous Patients
Launched by KU LEUVEN · Oct 6, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring how advanced technology can help predict changes in facial appearance for patients who have lost all their teeth, a condition known as edentulism. The study aims to improve the way doctors can visualize how a patient’s face might look after dental implants are placed, which can greatly enhance a person’s confidence and social interactions. Researchers are using a new method called a graph generative adversarial network, which is a type of artificial intelligence, to make these predictions quickly and accurately.
To participate in this study, individuals need to be at least 50 years old, have completely lost their teeth, and be in good health. Those who are interested must also be willing to undergo a facial scan. The trial is currently recruiting participants, and by joining, individuals can contribute to important research that may lead to better outcomes for future patients needing dental implants.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with complete edentulism,
- • aged 50 years or above,
- • in good physical health,
- Exclusion Criteria:
- • patients who refuse to participate in the study，
- • patients who cannot undergo facial scanning.
About Ku Leuven
KU Leuven, a prestigious research university located in Belgium, is renowned for its commitment to advancing medical science and improving patient care through innovative clinical trials. With a strong emphasis on interdisciplinary collaboration, KU Leuven integrates cutting-edge research with clinical practice, facilitating the development of new therapeutic strategies and medical technologies. The institution's robust infrastructure and expertise in various fields, including biotechnology, pharmacology, and public health, position it as a leader in conducting high-quality clinical research that adheres to rigorous ethical standards and regulatory requirements. Through its clinical trials, KU Leuven aims to contribute significantly to the global biomedical landscape and enhance health outcomes for diverse populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Leuven, Heverlee, Belgium
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported